Last reviewed · How we verify

Revefenacin 175 µg, Formoterol 20 µg

University of Tennessee Graduate School of Medicine · FDA-approved active Small molecule

Revefenacin 175 µg, Formoterol 20 µg is a Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA) Small molecule drug developed by University of Tennessee Graduate School of Medicine. It is currently FDA-approved for Chronic obstructive pulmonary disease (COPD) maintenance treatment. Also known as: Yupelri, Perforomist.

Revefenacin is a long-acting muscarinic antagonist that relaxes airway smooth muscle, while formoterol is a long-acting beta-2 agonist that further dilates airways, together providing bronchodilation for chronic obstructive pulmonary disease.

Revefenacin is a long-acting muscarinic antagonist that relaxes airway smooth muscle, while formoterol is a long-acting beta-2 agonist that further dilates airways, together providing bronchodilation for chronic obstructive pulmonary disease. Used for Chronic obstructive pulmonary disease (COPD) maintenance treatment.

At a glance

Generic nameRevefenacin 175 µg, Formoterol 20 µg
Also known asYupelri, Perforomist
SponsorUniversity of Tennessee Graduate School of Medicine
Drug classLong-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA)
TargetM3 muscarinic receptor; beta-2 adrenergic receptor
ModalitySmall molecule
Therapeutic areaRespiratory / Pulmonology
PhaseFDA-approved

Mechanism of action

Revefenacin blocks M3 muscarinic receptors on airway smooth muscle, preventing acetylcholine-induced bronchoconstriction. Formoterol activates beta-2 adrenergic receptors, increasing intracellular cAMP and causing smooth muscle relaxation. The combination provides dual bronchodilation through complementary mechanisms.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Revefenacin 175 µg, Formoterol 20 µg

What is Revefenacin 175 µg, Formoterol 20 µg?

Revefenacin 175 µg, Formoterol 20 µg is a Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA) drug developed by University of Tennessee Graduate School of Medicine, indicated for Chronic obstructive pulmonary disease (COPD) maintenance treatment.

How does Revefenacin 175 µg, Formoterol 20 µg work?

Revefenacin is a long-acting muscarinic antagonist that relaxes airway smooth muscle, while formoterol is a long-acting beta-2 agonist that further dilates airways, together providing bronchodilation for chronic obstructive pulmonary disease.

What is Revefenacin 175 µg, Formoterol 20 µg used for?

Revefenacin 175 µg, Formoterol 20 µg is indicated for Chronic obstructive pulmonary disease (COPD) maintenance treatment.

Who makes Revefenacin 175 µg, Formoterol 20 µg?

Revefenacin 175 µg, Formoterol 20 µg is developed and marketed by University of Tennessee Graduate School of Medicine (see full University of Tennessee Graduate School of Medicine pipeline at /company/university-of-tennessee-graduate-school-of-medicine).

Is Revefenacin 175 µg, Formoterol 20 µg also known as anything else?

Revefenacin 175 µg, Formoterol 20 µg is also known as Yupelri, Perforomist.

What drug class is Revefenacin 175 µg, Formoterol 20 µg in?

Revefenacin 175 µg, Formoterol 20 µg belongs to the Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA) class. See all Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA) drugs at /class/long-acting-muscarinic-antagonist-long-acting-beta-2-agonist-combination-lama-laba.

What development phase is Revefenacin 175 µg, Formoterol 20 µg in?

Revefenacin 175 µg, Formoterol 20 µg is FDA-approved (marketed).

What are the side effects of Revefenacin 175 µg, Formoterol 20 µg?

Common side effects of Revefenacin 175 µg, Formoterol 20 µg include Tremor, Headache, Palpitations, Tachycardia, Dry mouth.

What does Revefenacin 175 µg, Formoterol 20 µg target?

Revefenacin 175 µg, Formoterol 20 µg targets M3 muscarinic receptor; beta-2 adrenergic receptor and is a Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA).

Related